The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.
STE's risk disclosures shifted focus from geopolitical concerns to operational and reputational matters, replacing a Russia-Ukraine risk with broader geopolitical language while adding two substantive new risks around ESG liabilities and EO sterilization operations. The company maintained 22 unchanged risks while substantively modifying 11 existing disclosures, including those addressing regulatory approval processes, Cantel Medical acquisition debt, and operational management challenges. The net addition of one risk reflects STE's evolving risk profile toward emerging business considerations rather than external geopolitical factors.
Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.
🟢 New in Current Filing
The effects of geopolitical instability, including as a result of Russia’s invasion of Ukraine, may adversely affect us and create significant risks and uncertainties for our business, with the ultimate impact dependent on future developments, which are highly uncertain and unpredictable.
🔒
🟢 New in Current Filing
Expectations relating to ESG considerations expose us to potential liabilities, increased costs, reputational harm and other adverse effects on our business.
🔒
🟢 New in Current Filing
Our EO sterilization operations subject us to claims of liability and associated adverse effects.
🔒
🔴 No Match in Current Filing
The current military conflict between Russia and Ukraine and its implications on U.S., Canadian and European Union relations with Russia could cause long term geopolitical and economic instability that may impact our future operating results.
🔒
🔴 No Match in Current Filing
Our performance may suffer if we do not effectively manage our expanded operations.
🔒
🟡 Modified
We are subject to extensive regulatory requirements and must receive and maintain regulatory clearance or approval for many products and operations. Failure to receive or maintain, or delays in receiving, clearance or approvals may negatively impact our revenues, profitability, financial condition, or value.
🔒
🟡 Modified
We incurred a substantial amount of additional debt to complete the Cantel Medical acquisition. Our debt level may limit our financial and business flexibility.
🔒
🟡 Modified
Past and future business acquisitions may not be as accretive to STERIS’s earnings per share and cash flow from operations per share, which may negatively affect the market price of STERIS Shares.
🔒
🟡 Modified
We may fail to realize all of the anticipated benefits of an acquired business, or those benefits may take longer to realize than expected.
🔒
🟡 Modified
The integration of acquired businesses into STERIS may not be as successful as anticipated.
🔒
🟡 Modified
A pandemic or similar public health crises, such as COVID-19, could have a material adverse impact on ability to staff our operations.
🔒
🟡 Modified
Changes in tax treaties and trade agreements could negatively impact our costs, results of operations and earnings per share.
🔒
🟡 Modified
STERIS has incurred and expects to incur significant transaction and related costs in connection with business acquisitions and dispositions, which may be in excess of those anticipated.
🔒
🟡 Modified
We may be adversely affected by global climate change or by existing and future legal, regulatory or market responses to such change.
🔒
🟡 Modified
We have recorded goodwill and other intangible assets that could become impaired and result in material non-cash changes to our results of operation in the future.
🔒
🟡 Modified
Current economic and political conditions make tax rules in any jurisdiction subject to significant change.
🔒